急性缺血性卒中基于生物标志物的新型预后评分:CoRisk评分
研究在急性缺血性卒中患者中推导并外部验证基于和肽素的简化CoRisk评分,用于预测3个月不良结局。推导队列319例,验证队列783例,共1102例。验证队列中该评分校准良好,预测残疾和死亡的AUC为0.819(95%CI 0.787-0.849),正确分类75%患者,加入和肽素较未加入的净重分类指数为46%(95%CI 32-60)。
要点
- CoRisk评分包含和肽素水平、年龄、NIHSS评分和再通治疗。
- 外部验证显示预测3个月残疾和死亡的AUC为0.819,校准良好。
- 加入和肽素较未加入的净重分类指数为46%。
核心结论
- 基于生物标志物的CoRisk评分经外部验证,校准良好,预测残疾和死亡的表现优于不含和肽素的同一评分。
研究设计与样本
- 推导队列为瑞士巴塞尔大学医院前瞻性纳入的急性缺血性卒中患者319例。
- 验证队列为推导后前瞻性纳入的瑞士伯尔尼大学医院、巴塞尔大学医院及德国法兰克福a.M.的患者783例。
- 共1102例患者纳入分析,主要结局为3个月改良Rankin量表评分3至6分(残疾和死亡)。
主要发现
- 436例患者(40%)观察到不良结局。
- 验证队列中CoRisk评分预测3个月残疾和死亡的AUC为0.819(95%CI 0.787-0.849)。
- 校准后的CoRisk评分正确分类75%的患者(95%CI 72-78)。
- 含和不含和肽素的校准CoRisk评分之间的净重分类指数为46%(95%CI 32-60)。
关键数值与推荐
- CoRisk评分组件为和肽素水平、年龄、NIHSS评分和再通治疗。
- 和肽素水平在急性缺血性卒中后24小时内且任何再通治疗前采集的血浆中测量。
- 主要结局定义为3个月改良Rankin量表评分3至6分。
临床怎么用
- CoRisk评分可用于急性缺血性卒中后3个月残疾和死亡的预后评估。
- 评分包含和肽素、年龄、NIHSS评分和再通治疗信息。
- 和肽素测量需在卒中后24小时内且再通治疗前完成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To derive and externally validate a copeptin-based parsimonious score to predict unfavorable outcome 3 months after an acute ischemic stroke (AIS). METHODS: The derivation cohort consisted of patients with AIS enrolled prospectively at the University Hospital Basel, Switzerland. The validation cohort was prospectively enrolled after the derivation cohort at the University Hospital of Bern and University Hospital Basel, Switzerland, as well as Frankfurt a.M., Germany. The score components were copeptin levels, age, NIH Stroke Scale, and recanalization therapy (CoRisk score). Copeptin levels were measured in plasma drawn within 24 hours of AIS and before any recanalization therapy. The primary outcome of disability and death at 3 months was defined as modified Rankin Scale score of 3 to 6. RESULTS: Overall, 1,102 patients were included in the analysis; the derivation cohort contributed 319 patients, and the validation cohort contributed 783. An unfavorable outcome was observed among 436 patients (40%). For the 3-month prediction of disability and death, the CoRisk score was well calibrated in the validation cohort, for which the area under the receiver operating characteristic curve was 0.819 (95% confidence interval [CI] 0.787-0.849). The calibrated CoRisk score correctly classified 75% of patients (95% CI 72-78). The net reclassification index between the calibrated CoRisk scores with and without copeptin was 46% (95% CI 32-60). CONCLUSIONS: The biomarker-based CoRisk score for the prediction of disability and death was externally validated, was well calibrated, and performed better than the same score without copeptin. CLINICALTRIALSGOV IDENTIFIER: NCT00390962 (derivation cohort) and NCT00878813 (validation cohort).
引用
- De Marchis GM, Dankowski T, König IR, et al. A novel biomarker-based prognostic score in acute ischemic stroke: The CoRisk score. Neurology. 2019. PMID: 30824558. doi:10.1212/WNL.0000000000007177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。